HK1218721A1 - 包含利福平、異煙肼、乙胺丁醇和吡嗪酰胺的抗結核病的組合物及其製備方法 - Google Patents

包含利福平、異煙肼、乙胺丁醇和吡嗪酰胺的抗結核病的組合物及其製備方法

Info

Publication number
HK1218721A1
HK1218721A1 HK16106815.2A HK16106815A HK1218721A1 HK 1218721 A1 HK1218721 A1 HK 1218721A1 HK 16106815 A HK16106815 A HK 16106815A HK 1218721 A1 HK1218721 A1 HK 1218721A1
Authority
HK
Hong Kong
Prior art keywords
pyrazinamide
ethambutol
isoniazid
rifampicin
preparation
Prior art date
Application number
HK16106815.2A
Other languages
English (en)
Inventor
Kumar Amith
Madavan Bindu
Prasad Kum
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51212860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1218721A1 publication Critical patent/HK1218721A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16106815.2A 2013-07-26 2016-06-14 包含利福平、異煙肼、乙胺丁醇和吡嗪酰胺的抗結核病的組合物及其製備方法 HK1218721A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3343CH2013 2013-07-26
PCT/EP2014/065763 WO2015011163A1 (en) 2013-07-26 2014-07-22 Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.

Publications (1)

Publication Number Publication Date
HK1218721A1 true HK1218721A1 (zh) 2017-03-10

Family

ID=51212860

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106815.2A HK1218721A1 (zh) 2013-07-26 2016-06-14 包含利福平、異煙肼、乙胺丁醇和吡嗪酰胺的抗結核病的組合物及其製備方法

Country Status (18)

Country Link
US (1) US9814711B2 (zh)
EP (1) EP3024445B1 (zh)
JP (1) JP2017501117A (zh)
CN (1) CN105407874A (zh)
AU (1) AU2014295100B2 (zh)
CA (1) CA2918828A1 (zh)
CL (1) CL2016000180A1 (zh)
HK (1) HK1218721A1 (zh)
IL (1) IL243370A0 (zh)
MX (1) MX2016001156A (zh)
MY (1) MY174007A (zh)
PE (1) PE20160238A1 (zh)
PH (1) PH12016500118A1 (zh)
RU (1) RU2672879C2 (zh)
SG (1) SG11201510699WA (zh)
TW (1) TW201601716A (zh)
WO (1) WO2015011163A1 (zh)
ZA (1) ZA201600108B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001155A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.
KR20180126511A (ko) * 2016-04-08 2018-11-27 큐어테크 바이오 에이비 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도
EP3691619A1 (en) * 2017-10-05 2020-08-12 Quretech Bio AB Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
CN108186638A (zh) * 2018-03-08 2018-06-22 重庆华邦制药有限公司 异烟肼的药物组合物
AU2022405079A1 (en) * 2021-12-07 2024-06-27 An2 Therapeutics, Inc. Combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
NZ518216A (en) * 2000-08-09 2004-11-26 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
WO2002087547A1 (en) 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
RU2195937C1 (ru) * 2002-02-06 2003-01-10 НИИ молекулярной медицины ММА им. И.М.Сеченова Комбинированный противотуберкулезный препарат (ризобутол)
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
EP1711182A1 (en) * 2004-02-04 2006-10-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of antituberculosis drugs
TWI368509B (en) 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
AP2012006119A0 (en) 2009-07-31 2012-02-29 Cadila Pharmaceuticals Ltd Pharmaceutical composition of isoniazid.
WO2012013756A2 (fr) * 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
MX2016001155A (es) 2013-07-26 2016-04-29 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.
RU2682178C2 (ru) 2013-07-26 2019-03-15 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления

Also Published As

Publication number Publication date
EP3024445B1 (en) 2019-01-09
MX2016001156A (es) 2016-04-29
CA2918828A1 (en) 2015-01-29
WO2015011163A1 (en) 2015-01-29
PH12016500118A1 (en) 2016-04-25
IL243370A0 (en) 2016-02-29
RU2672879C2 (ru) 2018-11-20
AU2014295100B2 (en) 2019-01-03
US9814711B2 (en) 2017-11-14
JP2017501117A (ja) 2017-01-12
CN105407874A (zh) 2016-03-16
MY174007A (en) 2020-03-03
AU2014295100A1 (en) 2016-02-11
RU2016106336A3 (zh) 2018-05-17
EP3024445A1 (en) 2016-06-01
SG11201510699WA (en) 2016-01-28
RU2016106336A (ru) 2017-08-31
CL2016000180A1 (es) 2016-06-24
US20160158226A1 (en) 2016-06-09
ZA201600108B (en) 2017-04-26
TW201601716A (zh) 2016-01-16
PE20160238A1 (es) 2016-05-05

Similar Documents

Publication Publication Date Title
HK1218721A1 (zh) 包含利福平、異煙肼、乙胺丁醇和吡嗪酰胺的抗結核病的組合物及其製備方法
HK1212207A1 (zh) 經取代吡咯並嘧啶化合物、其組合物及其治療方法
EP3169326A4 (en) Suppression of myeloid derived suppressor cells and immune checkpoint blockade
HK1217486A1 (zh) 作爲β-分泌酶抑制劑的全氟化環丙基稠合的 -噁嗪- -胺化合物以及其使用方法
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
PL3206756T3 (pl) Zastosowanie heksadeka-8,15-dienalu jako aromatycznej substancji chemicznej
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
EP2957615A4 (en) COMPOSITION FOR FORMATION OF HYDROFUGGED FILMS AND USE THEREOF
IL244268A0 (en) Heterocyclic compounds and methods of use
HK1211377A1 (zh) 執行用於增益確定的濾波的系統及方法
EP3019477A4 (en) Heterocyclic compounds and methods of their use
HK1210257A1 (zh) 用於材料驗證的隱蔽圖層
HK1232291A1 (zh) 用於生物分子的收集、穩定和洗脫的基材和方法
IL253204B (en) Trifluoroacethydrazide compound, method for its preparation and use for preparing a medical preparation
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
EP2969579A4 (en) TREATMENT OF AMMONIUM OCTAMOLYBDATE
EP2994461A4 (en) Methods of treating skin conditions using cyclolignan compounds
PL2657326T3 (pl) Zastosowanie związków kompleksujących jony metali do stabilizacji aromatu
IL243133B (en) Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
EP3211087A4 (en) Method for screening compound specifically inhibiting formation of caveolae in cancer cells, screening kit, vector and transformant to be used in kit, and method for selecting patient adaptable for molecular-targeting drug
GB2525530B (en) Treatment of hard surfaces
ZA201404780B (en) Composition for use in treatment of diabetes
AU2014901768A0 (en) Heterocyclic compounds and use of same